GSK, Prosensa muscular dystrophy drug misses study goal
LONDON, Sept 20
LONDON, Sept 20 (Reuters) - An experimental drug for Duchenne muscular dystrophy from GlaxoSmithKline and Prosensa failed to meet its goal in a late-stage clinical trial, the companies said on Friday.
The drug, drisapersen, did not show a statistically significant improvement in the distance that patients could walk in six minutes compared to placebo in the Phase III test.
Trending On Reuters
Strategies for making the most of your donations - from how to grow the money you plan to give to how to withdraw it with minimal tax implications. Video